Table 1.
Baseline Characteristics
| Characteristic (n,%) | All (n = 427) | CAD (n = 290) | DCM (n = 137) | P Value |
|---|---|---|---|---|
| Age, years | 58±14 | 62±10 | 49±15 | <0.001 |
| Male gender | 336 (79%) | 248 (86%) | 88 (64%) | <0.001 |
| Left ventricular ejection fraction, % | 27±9 | 27±7 | 28±12 | NS |
| History of myocardial infarction | 261 (61%) | 261 (61%) | NA | NA |
| NYHA class at time of ICD implantation | ||||
| NYHA I‐II | 347 (82%) | 255 (88%) | 95 (70%) | <0.001 |
| NYHA III‐IV | 77 (18%) | 37 (12%) | 40 (30%) | |
| Previous revascularization | ||||
| CABG | 90 (21%) | 90 (31%) | NA | NA |
| PCI | 141 (33%) | 141 (49%) | NA | NA |
| History of atrial fibrillation | 112 (26%) | 80 (28%) | 32 (24%) | NS |
| QRS duration, ms | 116±26 | 117±26 | 112±27 | NS |
| QRS >0.12 s | 133 (31%) | 100 (35%) | 33 (24%) | 0.034 |
| Serum creatinine (μmol/L) | 97±41 | 99±37 | 94±46 | NS |
| eGFR (mL/min/1.73 m2) | 78±26 | 76±25 | 80±26 | 0.07 |
| Diabetes | 88 (21%) | 70 (24%) | 18 (13%) | 0.01 |
| Renal failure | 106 (25%) | 79 (27%) | 27 (20%) | 0.1 |
| Implanted devices | ||||
| Single‐chamber ICD | 317 (74%) | 224 (77%) | 93 (68%) | 0.044 |
| Dual‐chamber ICD | 110 (26%) | 66 (28%) | 44 (32%) | |
| Cardiovascular medication | ||||
| Amiodarone | 46 (11%) | 29 (10%) | 17 (13%) | NS |
| Beta‐blocker | 332 (78%) | 238 (82%) | 94 (69%) | 0.004 |
| Digoxin | 87 (20%) | 53 (18%) | 34 (25%) | 0.1 |
| ACE inhibitor | 330 (78%) | 228 (79%) | 102 (75%) | NS |
| Diuretic | 252 (59%) | 170 (59%) | 82 (60%) | NS |
| Statin | 265 (62%) | 238 (82%) | 27 (20%) | <0.001 |
Abbreviations: ACE, angiotensin‐converting enzyme; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter‐defibrillator; NA, not applicable; NS, not significant; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.